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Onno C. van Schayck2,4, Aziz Sheikh2,4,8, Frank de Vries4,7,9,10 & Patrick Souverein7
We investigated the association between introduction of smoke-free legislation in the UK (March 
2006 for Scotland, April 2007 for Wales and Northern Ireland, and July 2007 for England) and the 
incidence of respiratory diseases among children. We extracted monthly counts of new diagnoses of 
wheezing/asthma and RTIs among children aged 0–12 years from all general practices in the Clinical 
Practice Research Datalink during 1997–2012. Interrupted time series analyses were performed 
using generalised additive mixed models, adjusting for underlying incidence trends, population 
size changes, seasonal factors, and pandemic influenza, as appropriate. 366,642 new wheezing/
asthma diagnoses and 4,324,789 RTIs were observed over 9,536,003 patient-years. There was no 
statistically significant change in the incidence of wheezing/asthma after introduction of smoke-free 
legislation in England (incidence rate ratio (IRR) 0.94, 95% CI 0.81–1.09) or any other UK country 
(Scotland: IRR 0.99, 95% CI 0.83–1.19; Wales: IRR 1.09, 95% CI 0.89–1.35; Northern Ireland: IRR 0.96, 
95% CI 0.76–1.22). Similarly no statistically significant changes in RTI incidence were demonstrated 
(England: IRR 0.95, 95% CI 0.86–1.06; Scotland: IRR 0.96, 95% CI 0.83–1.11; Wales: IRR 0.97, 95% CI 
0.86–1.09; Northern Ireland: IRR 0.90, 95% CI 0.79–1.03). There were no demonstrable reductions in 
the incidence of paediatric wheezing/asthma or RTIs following introduction of smoke-free legislation 
in the UK.
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Exposure to second-hand smoke (SHS) is estimated to be responsible for over 600,000 deaths and almost 
11 million disability-adjusted life years (DALYs) worldwide each year1. Children account for over a 
quarter of these deaths and over half of the associated DALYs, which are almost entirely attributable to 
respiratory diseases1. There is clear evidence demonstrating that SHS exposure in the population can 
effectively be reduced by the implementation of legislation prohibiting smoking in enclosed public places 
and the workplace2. Associations between the introduction of smoke-free legislation and reductions in 
respiratory, cardiovascular, and cerebrovascular hospitalisations among adults are well recognised, and 
these are most pronounced in countries with the most comprehensive laws3. However, comprehensive 
smoke-free laws currently cover only about a sixth of the world’s population4.
Associations between smoke-free legislation and improved early-life outcomes are now increasingly 
becoming established. In a recent meta-analysis, 10% reductions in the incidence of preterm birth and 
of paediatric asthma exacerbations requiring hospital attendance were demonstrated following introduc-
tion of smoke-free laws5. Following the introduction of smoke-free legislation in England, a reduction 
in hospital admissions for acute RTIs among children was furthermore identified6. These observations 
are in line with the large body of epidemiological and mechanistic literature demonstrating that SHS 
exposure is associated with a range of paediatric respiratory diseases, including RTIs and asthma7–9. 
Reduced forced expiratory volume in one second (FEV1), increased airway hyper-reactivity and allergic 
sensitisation, and impairment of mucociliary clearance and the host response to infections have all been 
implicated as likely mediators of these associations10–12.
As the majority of the disease burden of paediatric respiratory diseases− including asthma and 
RTIs− lies in primary care, the lack of studies assessing the impact of smoke-free legislation on GP 
consultations is an important knowledge gap in the appreciation of the association between smoke-free 
legislation and child health5.
We aimed to study the association between the introduction of smoke-free legislation in each of the 
four countries in the UK and incidence changes in asthma and RTIs in general practices among children 
aged 12 and younger.
Methods
This study was performed according to a pre-specified protocol that was approved by the Independent 
Scientific Advisory Committee of the Clinical Practice Research Datalink (CPRD; reference: 13_156 (see 
Supplementary Methods online)). We investigated the impact of smoke-free legislation on the incidence 
of RTIs and new diagnoses of wheezing/asthma among children aged ≤ 12 years who contributed data 
to CPRD during 1997-2012. Separate analyses were undertaken for each UK country. This was important 
because smoke-free legislation was introduced at different time points.
Ethical approval. The CPRD has been granted Multiple Research Ethics Committee approval (05/
MRE04/87) to undertake purely observational studies. The work of CPRD is also covered by National 
Information Governance Board Ethics and Confidentiality Committee approval ECC 5-05 (a) 2012. This 
study was furthermore reviewed by the National Health Services South East Scotland Research Ethics 
Service and The University of Edinburgh’s Centre for Population Health Sciences Ethics Review Group, 
who provided exemptions from formal ethical assessment based on the use of anonymised, unidentifiable 
data.
Introduction of the smoke-free laws. The intervention under study was the law prohibiting smok-
ing in enclosed public places and the workplace that was implemented at different time points in each 
country: 26 March 2006 in Scotland13, 2 April 2007 in Wales14, 30 April 2007 in Northern Ireland15, and 
1 July 2007 in England16. From these dates onwards, smoking was prohibited in virtually all enclosed 
public places and workplaces; compliance with the smoke-free law has been high in each country at 97 
to 98%13,14,17,18.
Outcomes. We stipulated two primary outcomes a priori: the monthly incidence of new diagno-
ses of wheezing/asthma and the monthly incidence of RTI episodes. Wheezing/asthma was considered 
newly diagnosed when a relevant diagnostic Read code (see original study protocol in Supplementary 
Methods online) was recorded in a child’s medical records and/or when a prescription for asthma-related 
medication was issued (see original study protocol in Supplementary Methods online) in a child who 
had no wheezing/asthma diagnosis or related prescriptions previously recorded. Given the difficulty in 
distinguishing between wheezing disorders and asthma, especially in young children19, we considered 
an inclusive set of diagnostic codes. Medications included oral leukotriene receptor antagonists, and 
inhaled beta-2-agonists, cromoglycates, ipratropium bromide, and glucocorticoids. The first recording of 
wheezing/asthma or a related prescription was considered the index date. Children moving into a GP 
practice were considered prevalent cases if wheezing/asthma was recorded before or on the first day of 
registration with that practice.
RTIs, including both acute lower RTIs (LRTIs; including: bronchitis, bronchiolitis, pneumonia (includ-
ing influenza pneumonia)) and acute upper RTIs (URTIs; including: otitis media, mastoiditis, rhinitis, 
sinusitis, pharyngitis, laryngitis, tonsillitis, epiglottitis, tracheitis, influenza (excluding pneumonia)), were 
identified using Read codes (see original study protocol in Supplementary Methods online for full list of 
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diagnostic codes). Multiple consultations within a 14-day period were considered a single RTI episode, 
with the exception of LRTIs, which were allowed a preceding consultation for an URTI. As the majority 
of common childhood RTIs resolve within two weeks20, RTIs occurring beyond the 14-day period were 
considered new events.
The primary analysis was carried out for England, which had the largest population available for 
analysis. As secondary outcomes in England we considered the incidence of LRTIs and URTIs separately. 
Analyses for Scotland, Wales, and Northern Ireland were restricted to the two primary outcomes only.
Data sources and handling. Data were obtained from CPRD (previously called the General Practice 
Research Database (GPRD)), which currently covers a representative 8.5% of the UK population21,22. 
We counted all incident wheezing/asthma diagnoses and RTI episodes between 1 January 1997 and 
31 December 2012 occurring in children aged ≤ 12 years registered in practices who contributed 
‘up-to-standard’ data at the time of the event (i.e. data meeting specific quality criteria as defined by 
CPRD)23. Incident wheezing/asthma and RTI counts were separately aggregated per month for each 
country. Separate counts for LRTIs and URTIs were also recorded.
The at-risk-population in a given month consisted of all children registered with a GP practice that 
contributed to up-to-standard data for at least part of that month. For analysis of wheezing/asthma 
diagnoses, prevalent cases were excluded from the denominator. We restricted our analyses to children 
aged ≤ 12 years in order to minimise potential confounding by active smoking.
Statistical analyses. Monthly counts for each outcome were analysed in the statistical package R 
version 2.14.0, using the function ‘gamm’ from the library ‘mgcv’24. We used Poisson generalised addi-
tive mixed models (GAMMs) to calculate an incidence rate ratio (IRR) for each outcome, indicating the 
change in its incidence in the period after the introduction of smoke-free legislation compared to the 
period beforehand. We used GAMM models because their flexibility allows the effects of both linear and 
non-linear terms to be estimated, and autocorrelation between data points to be accounted for24.
Each model included variables specified a priori to account for differences in the number of days in 
each month, the number of days GP practices were open (i.e. excluding weekends and public holidays), 
and an offset term indicating the size of the at-risk-population. Smoke-free legislation was modelled 
using a dummy variable coded ‘0’ before its introduction in each country, and ‘1’ afterwards, thus allow-
ing for an instantaneous (‘step’) change in the incidence of the outcome. Statistical significance was 
accepted at a two-tailed alpha of 0.05.
A backward selection procedure using a cut-off p-value of 0.05 was employed to allow for additional 
inclusion of the following variables: a thin plate spline or linear term to model any underlying time 
trends (using the effective degrees of freedom of the spline to assess whether a non-linear or linear term 
was most appropriate); a cyclic cubic spline to model seasonal variations; monthly mean temperature 
(average of the mean monthly maximum and minimum temperatures across all Meteorological Office 
weather stations in each country)25. Following initial analysis, in a minor deviation from the protocol, 
three additional covariates were considered to enable modelling of residual seasonality within the data: 
RTI consultation rate (in the model of wheezing/asthma incidence) and two dummy variables to rep-
resent school holidays. Relative troughs in the incidence of respiratory outcomes during school holiday 
periods are well recognised in both preschool and school-aged children26. We therefore defined a dummy 
variable coded ‘1’ in August of each year and ‘0’ in all other months to model the impact of the long 
summer holiday, and a second dummy to account for the Easter (April) and Christmas (December) 
holidays. These holidays are typically of two weeks’ duration, and could not be more accurately specified 
within our monthly data; we did not attempt to model the impact of the one-week ‘half-term’ holidays. 
Given the established association between RTIs and childhood wheezing disorders27, RTI incidence was 
included in the analyses of new wheezing/asthma diagnoses. This variable was log-transformed to nor-
malise its distribution.
In addition, initial examination of the RTI count data suggested higher than usual counts in July 2009 
which we hypothesised to be attributable to pandemic influenza; the highest GP consultation rates for 
influenza-like illness in UK sentinel practices occurred in week 29 (ending 19 July)28. Our preliminary 
models failed to adequately capture these values. We therefore defined a dummy variable for inclusion in 
our RTI models to model this peak pandemic period, coded ‘1’ in July 2009 and ‘0’ in all other months.
We observed overdispersion in the Poisson models, which we corrected using a quasi-Poisson 
model. Model residuals were examined to assess normality and identify any residual autocorrelation. 
Autoregressive or moving average terms were included in the model as appropriate, using the residual 
autocorrelation function and partial autocorrelation function to determine the order of these terms. The 
final selection of covariates for each model is displayed in Supplementary Table S1 online.
Subgroup analyses. We performed pre-defined subgroup analyses by age group (0–4 years; 5–12 
years) to assess potential differential effects of smoke-free legislation in preschool and school-age 
subgroups.
Sensitivity analyses. Introduction of the Quality and Outcomes Framework (QOF) in April 2004 
provided GPs with a financial incentive to record asthma diagnoses, which might be hypothesised to 
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produce sudden changes in incidence rates. Therefore, we also ran our model for wheezing/asthma diag-
noses in England on a restricted time series from April 2004 only, as defined a priori.
Results
A total of 9,536,003 patient-years of data was analysed, during which 366,642 new wheezing/asthma 
diagnoses and 4,324,789 RTI episodes were observed (Table 1). 15,433 URTI consultations were followed 
by a LRTI episode within 14 days. Temporal patterns in the number of practices contributing data are 
given in Supplementary Fig. S1 online. Monthly rates of new wheezing/asthma diagnoses and RTIs for 
each country are displayed in Figs  1 and 2, respectively. Mean monthly wheezing/asthma incidences 
across the whole study period per 1,000 children at risk ranged from 3.7 for Scotland to 5.4 for Northern 
Ireland (overall mean 4.3). Comparable figures for RTIs ranged from 26.3 for Scotland to 42.1 for Wales 
(overall mean 37.8).
The introduction of smoke-free legislation in England was not associated with a statistically signif-
icant change in the number of new wheezing/asthma diagnoses in GP practices: IRR 0.94 (95% CI 
0.81–1.09, p = 0.412). Similarly, no significant impact of smoke-free legislation on new diagnoses of 
wheezing/asthma was observed in Scotland, Wales, or Northern Ireland (Table 2).
There was no statistically significant change in the incidence rate of RTI episodes in the GP practice 
following introduction of smoke-free legislation in England (IRR 0.95 (95% CI 0.84–1.06), p = 0.399). 
Neither was a significant change observed in the other UK countries (Table 2).
The vast majority of RTI episodes were URTIs (Table 1 and Fig. 3). There was no statistically signifi-
cant impact of smoke-free legislation on either URTI episodes (IRR 0.95 (95% CI 0.86–1.06), p = 0.401) 
or LRTI episodes (IRR 0.96 (95% CI 0.81–1.15), p = 0.678) in separate analyses for England.
New wheezing/asthma diagnoses and RTI episodes both occurred more frequently among preschool 
children than among school-age children (Figs 4 and 5). No significant impact of smoke-free legislation 
on either outcome was seen in England irrespective of age group (Table 3).
Restriction of the time series analysis to the period following the introduction of the QOF did not 
affect the impact estimation of smoke-free legislation on the incidence rate of new wheezing/asthma diag-
noses in England, which remained non-statistically significant: IRR 0.93 (95% CI 0.84–1.02), p = 0.123.
Country, age 
group
Asthma Respiratory tract infections
Events 
(n)
Patient-years 
observed (n)
Mean 
incidence per 
1,000 patient-
months
All RTI 
events (n)
URTI 
events (n)
LRTI 
events (n)
Patient-
years 
observed (n)
Mean RTI 
incidence per 
1,000 patient-
months
Mean URTI 
incidence per 
1,000 patient-
months
Mean LRTI 
incidence per 
1,000 patient-
months
England
 0–4 years 197,942 2,220,194 7.4 2,030,265 1,949,508 92,166 2,679,568 63.1 60.6 2.9
 5–12 years 96,092 3,500,493 2.3 1,525,504 1,503,407 23,467 4,940,896 25.7 25.4 0.4
 Total 294,034 5,720,687 4.3 3,555,769 3,452,915 115,633 7,620,464 38.9 37.8 1.3
Scotland
 0–4 years 18,905 252,940 6.2 150,990 144,936 6,870 295,511 42.6 40.9 1.9
 5–12 years 10,372 408,272 2.1 118,462 116,979 1,598 557,239 17.7 17.5 0.2
 Total 29,277 661,212 3.7 269,452 261,915 8,468 852,750 26.3 25.6 0.8
Wales
 0–4 years 19,067 206,206 7.7 200,546 191,956 9,697 250,071 66.8 64.0 3.2
 5–12 years 9,344 334,719 2.3 165,071 162,645 2,559 473,702 29.0 28.6 0.5
 Total 28,411 540,925 4.4 365,617 354,601 12,256 723,773 42.1 40.8 1.4
Northern Ireland
 0–4 years 10,681 87,983 10.1 75,931 72,843 3,526 115,320 54.9 52.6 2.5
 5–12 years 4,239 140,867 2.5 58,020 57,196 869 223,695 21.6 21.3 0.3
 Total 14,920 228,850 5.4 133,951 130,039 4,395 339,015 33.0 32.0 1.1
All countries
 0–4 years 246,595 2,770,073 7.4 2,457,732 2,359,243 112,259 3,340,470 61.3 58.9 2.8
 5–12 years 120,047 4,394,408 2.3 1,867,057 1,840,227 28,493 6,195,533 25.1 24.8 0.4
 Total 366,642 7,151,674 4.3 4,324,789 4,199,470 140,752 9,536,003 37.8 36.7 1.2
Table 1.  Event counts and patient-years observed by diagnosis, country, and age group. 
RTI = respiratory tract infection; URTI = upper respiratory tract infection; LRTI = lower respiratory tract 
infection.
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Discussion
In this large observational study we found no association between the introduction of smoke-free legis-
lation and the number of new wheezing/asthma cases or RTI episodes among children presenting to a 
GP in any of the four countries in the UK.
Analysing over 350,000 new wheezing/asthma cases and more than four million RTI episodes over a 
16-year period in four countries, this study is one of the largest evaluations of the impact of smoke-free 
legislation on child health ever undertaken5. It is unique in its focus on evaluation of GP consultations, as 
previous studies investigated hospital-based outcomes5. CPRD is the largest longitudinal GP database in 
Figure 1. Incidence trends in new wheezing/asthma diagnoses. (A) England; (B) Scotland; (C) Wales;  
(D) Northern Ireland. Dashed line indicates introduction of smoke-free legislation.
Figure 2. Incidence trends in new respiratory tract infection (RTI) diagnoses. (A) England; (B) Scotland; 
(C) Wales; (D) Northern Ireland. Dashed line indicates introduction of smoke-free legislation.
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the world, and its validity is well established22. We included only data that met pre-specified data quality 
criteria and used well-defined case definitions, using diagnostic and prescription data. We focused on 
children aged 12 and younger to minimise potential confounding by active smoking. The unique geo-
graphic coverage of CPRD furthermore allowed us to replicate the methodology in all four UK countries, 
where smoke-free legislation was introduced at different time points, further strengthening the findings.
This study also has a number of limitations. Inherent to the evaluation of national public health inter-
ventions, randomised allocation of the intervention was not possible29. We therefore employed an inter-
rupted time series analysis design, which is among the strongest designs for evaluation of public health 
interventions29. Nonetheless, the observational design and lack of a control group are limitations of the 
current study that restrict causal inference. Minor modifications to the original study protocol, deemed 
necessary after initial examination of the CPRD data, were specified. This is important as changes in 
approach may affect study findings30.
A variety of statistical models have been used in the past to assess the association between smoke-free 
legislation and health outcomes3,5,29, and may result in different findings5,31. Particular strengths of the 
GAMM modelling approach include its ability to deal with issues that commonly complicate temporal 
data analysis, such as the need to account for underlying non-linear long-term and seasonal variations 
in the outcome, and temporal autocorrelation. However, the modelling approach did not allow us to 
take into account potential individual-level confounding or data dependency resulting from recurrent 
RTI events within individuals.
In interrupted time series analysis, it is assumed that all other factors influencing the outcome, includ-
ing the composition of the study population, remain unchanged. With patients and GP practices enter-
ing and leaving the database over time, consequential temporal variation in population characteristics 
Country
Asthma Respiratory tract infections
IRR 95% CI p-value IRR 95% CI p-value
England 0.94 0.81–1.09 0.412 0.95 0.86–1.06 0.399
Scotland 0.99 0.83–1.19 0.946 0.96 0.83–1.12 0.620
Wales 1.09 0.89–1.35 0.406 0.97 0.86–1.09 0.641
Northern Ireland 0.96 0.76–1.22 0.745 0.90 0.79–1.03 0.132
Table 2.  Impact of smoke-free legislation on primary outcomes. See Supplementary Table S1 online for 
details of the variables included in each model. IRR = incidence rate ratio; CI = confidence interval.
Figure 3. Incidence trends in upper and lower respiratory tract infection episodes in England. (A) upper 
respiratory tract infections (URTI); (B) lower respiratory tract infections (LRTI). Dashed line indicates 
introduction of smoke-free legislation. Note the different scales on the y-axis.
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may have introduced bias. We are unaware of a systematic assessment of the potential limitations of 
using interrupted time series GAMM in this setting. Temporal constancy is also violated if the degree 
of recording of the outcome changes over time. A sensitivity analysis suggested no confounding by the 
2004 introduction of QOF. No abrupt incidence rate deviations that could suggest temporal changes 
Figure 4. Incidence trends in new wheezing/asthma diagnoses in England according to age group.  
(A) 0–4 years; (B) 5–12 years. Dashed line indicates introduction of smoke-free legislation. Note the 
different scales on the y-axis.
Figure 5. Incidence trends in respiratory tract infection (RTI) episodes in England according to age 
group. (A) 0–4 years; (B) 5–12 years. Dashed line indicates introduction of smoke-free legislation. Note the 
different scales on the y-axis.
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in recording were present in any outcome and temporal patterns of GP consultations generally paral-
leled those of asthma and RTI hospitalisations6,32. To minimise the risk of under-recording of wheezing/
asthma, we included medication prescriptions in the definition.
Reliable case definition in general practice is challenging. This is particularly true for asthma, which is 
a difficult diagnosis, especially among preschool children19. Our highly inclusive list of diagnostic codes 
may have led to over-diagnosis, and it is possible that stricter case definitions would have generated 
different impact estimations. Although the overall validity of RTI diagnoses in CPRD has been shown 
to be very high at 97.2% (95%CI 85.5–99.9)22, we are unaware of similar data for asthma22. Wheezing/
asthma cases and RTI episodes may have been missed because they presented primarily in secondary 
care, although their contribution is likely to be minimal. A particular issue concerned the identification 
of prevalent asthma cases. Previous research using GPRD data showed that patients were more likely to 
be diagnosed with asthma in the first three months after their GP practice becoming up-to-standard, 
probably due to misclassification of prevalent cases as incident cases33. In our study this is likely to be of 
only minor importance as most children entered the database shortly after birth.
The effect estimates in our study had wide confidence intervals. Using the standard error of the IRRs 
derived from our models we retrospectively estimated the minimum effect size that could be detected as 
statistically significant at approximately 15–20%34, a larger decline than our point estimates. The primary 
determinant of the uncertainty around our estimates and thus of the reduced power, despite a very large 
study population and extensive study period, is the ability of GAMM to capture the month-by-month 
variability in the time series. Despite additional efforts to adequately model this, an important degree of 
unexplained variation remained, hence the wide confidence intervals observed. In an unplanned sensitiv-
ity analysis (not shown), analysing weekly rather than monthly data resulted in similar effect sizes and no 
improvement in power. Temporal variation in meteorological and environmental factors, RTI epidemics, 
and demographic changes due to the dynamic character of the cohort not accounted for in our models 
may contribute to the unexplained variation.
Many of the issues described above could potentially be addressed by performing additional sensi-
tivity analyses. As outlined in our study protocol, given the number of planned analyses and the corre-
sponding risks associated with multiple testing, we restricted our analyses to those presented.
Unequivocal evidence supports the link between tobacco smoke exposure and adverse respiratory 
outcomes among children and adults, including RTIs and the development and exacerbation of chronic 
lung disorders such as asthma and chronic obstructive pulmonary disease7–9,12. In line with these find-
ings, meta-analyses show that smoke-free legislation is associated with reductions in hospital attendance 
for respiratory infections among adults, and for asthma among both children and adults3,5. These effects 
are likely attributable to reductions in second-hand smoke exposure in the public as well as the home 
environment2,5. In England, between 2006 and 2008 the proportion of smoke-free homes among children 
with smoking parents increased from 36% to 48% (p < 0.001), and the proportion of children with unde-
tectable salivary cotinine, a marker of SHS exposure, increased from 34% to 41% (p < 0.001)35. Three UK 
studies evaluated the impact on paediatric respiratory health6,32,36, demonstrating substantial reductions 
in asthma hospitalisations following smoke-free legislation in England (immediate: IRR 0.91, 95% CI 
0.89–0.93; annual: IRR 0.97, 95% CI 0.96–0.98) and in Scotland (gradual: IRR 0.82, 95% CI 0.78–0.85), 
as well as in RTI admissions in England (immediate: IRR 0.965, 95% CI 0.953–0.977; annual: IRR 0.995, 
95% CI 0.991–0.999). Retrospective power calculation demonstrated that our study likely lacked power 
to detect differences in the same order of magnitude. Adequate comparison of these studies with our 
work is complicated by methodological differences (e.g. evaluation of hospitalisations versus GP consul-
tations; different coding systems; the use of negative binomial regression versus GAMM; the evaluation 
of gradual versus immediate incidence changes; and model adjustment for demographic variables)6,32,36.
It is possible that indeed no significant reduction in RTI consultations and new wheezing/asthma 
cases in general practice followed the introduction of smoke-free legislation in England, as our findings 
suggest. For RTIs one could speculate that smoke-free laws preferentially reduce the incidence of severe 
and complicated cases, which are more likely to require hospitalisation3,6, rather than overall RTI inci-
dence. This fits well with the recognised positive association between SHS exposure and RTI severity 
among children37,38. As for asthma, smoke-free legislation may reduce the frequency of exacerbations as 
indicated by hospital attendance5, rather than the actual incidence of new wheezing/asthma diagnoses, as 
evaluated in the current study. In support of this concept, US children living in regions with a smoking 
Age group
Asthma Respiratory tract infections
IRR 95% CI p-value IRR 95% CI p-value
0–4 years 0.96 0.84–1.10 0.580 0.97 0.88–1.08 0.621
5–12 years 0.92 0.77–1.10 0.367 0.90 0.78–1.03 0.114
Table 3.  Impact of smoke-free legislation in England on primary outcomes by age group. See 
Supplementary Table S1 online for details of the variables included in each model. IRR = incidence rate 
ratio; CI = confidence interval.
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ban were shown to have lower rates of asthma symptoms, but not of current asthma, compared to those 
living in regions without a ban39. We did not attempt to assess the contribution of asthma exacerbations 
in our study, due to uncertainty regarding their reliable differentiation from regular asthma visits.
The current study leaves a number of questions unanswered. Variations in case definition and sensi-
tivity analyses to explore data validity issues should be considered, as well as the additional inclusion of 
older age groups and non-respiratory disease outcomes that can be expected to benefit from smoke-free 
legislation2,3,5. Parallel evaluations of primary and secondary care outcomes in the same population are 
necessary to more precisely identify the areas where smoke-free environments exert their primary ben-
efit. As the largest burden of morbidity and mortality associated with respiratory disorders lies within 
low- and middle-income countries, the lack of health impact studies of smoke-free environments in these 
regions needs to be addressed5.
In conclusion, despite strong existing evidence for reductions in severe adverse early life health 
outcomes following smoke-free legislation, no significant changes in the incidence of GP diagnoses of 
wheezing/asthma or RTIs among children were demonstrated in this large study in four UK countries.
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